Join us   Log in  

PHARMASPIRE - Volume 12, Issue 1, January-March, 2020

Pages: 1-5

Date of Publication: 14-Jun-2022

Print Article   Download XML  Download PDF

Review on nanotechnologies in ocular drug delivery

Author: Gurmeet Singh, Amandeep Singh, Deepak Sharma, Raj Kumar Narang

Category: Pharmaceutics


Treatment with traditional ocular dose structure has a wide range of issues such as obscured vision, loss of medication by seepage, irritation, non-maintain activity, persistent noncompliance, nature of medication, and so on furthermore diminishes the visual bioavailability of medication. To minimize these issues, novel ocular dose structures are utilized for some visual diseases. Distinctive novel ocular measurement frames like controlled dose shape that is inserts, liposomes, nanoparticles, visual supplements, contact lenses, iontophoresis, and so on, have managed the influx of medication particles by moderate degradation of the polymer. These measurement frames build the contact time of medication particles with ocular tissues, which infiltrates the medication particles into more profound tissues of the eye furthermore expands the visual bioavailability of medication. Novel medication conveyance through the ophthalmic course has real change for future perspectives.

Keywords: Emulsion, implants, nanomicelles, ocular delivery, solution, suspensions


1. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008;13:144-51.

2. Bucolo C, Maltese A, Drago F. When nanotechnology meets the ocular surface. Expert Rev Ophthalmol 2008;3:325-32.

3. Singh A, Negi D, Mishra N, Baldi A. Recent trends in ocular drug delivery. Pharmaspire 2018;10:55-63.

4. Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 2006;58:1258-68.

5. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010;17:467-89.

6. Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use. Drug Saf 2002;25:233-50.

7. Vérétout F, Delaye M, Tardieu A. Molecular basis of eye lens transparency: Osmotic pressure and X-ray analysis of α-crystallin solutions. J Mol Biol 1989;205:713-28.

8. Pavithra KG, Jaikumar V, Kumar PS, SundarRajan P. A review on cleaner strategies for chromium industrial wastewater: Present research and future perspective. J Clean Prod 2019;228:580-93.

9. Ueda CT, Shah VP, Derdzinski K, Ewing G, Flynn G, Maibach H, et al. Topical and transdermal drug products. Pharm Forum 2009;35:750-64.

10. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: A novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul 2008;1:238-57.

11. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res 2010;1:381.

12. Imam S, Bansal A, Bushetti SS, Singh A, Chopra H. Novel ocular dosage form in the treatment of glaucoma. Pharm Res 2009;1:72-81.

13. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348-60.

14. Singh A, Dogra TS, Mandal UK, Narang RK. Novel approaches for ocular drug delivery: A review. Int J BioPharm Res 2019;8:2722-35.

15. Rathore KS, Nema RK, Sisodia SS. An overview and advancement in ocular drug delivery systems. Int J Pharm Sci Res 2010;10:11-23.

16. Kompella UB, Amrite AC, Ravi RP, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013;36:172-98.

17. Singh A, Rath G, Singh R, Goyal AK. Nanofibers: An effective tool for controlled and sustained drug delivery. Current Drug Deliv 2018:15:155-66.

18. Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adenoassociated viral vectors. Methods 2002;28:267-75.